AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?

When considering which healthcare stock to buy in 2026, investors must weigh the current income potential against future growth prospects. AbbVie Inc. (NYSE:ABBV) and Novo Nordisk A/S (NYSE:NVO) are two prominent pharmaceutical companies that present distinct investment opportunities. AbbVie is shifting its focus away from its reliance on a single blockbuster drug and pouring resources into immunology and oncology research.

Novo Nordisk, on the other hand, has witnessed a surge in demand for its obesity medications, capitalizing on the growing importance of metabolic health. Both companies operate within a highly competitive pharmaceutical industry, but they offer different risk and reward characteristics. AbbVie operates globally, concentrating on developing advanced therapies for complex health conditions, such as immunology, oncology, and neuroscience.

The company's most recent annual report for 2025 emphasized its strategy of targeting physicians and government payers, with its U.S. distribution relying heavily on three major wholesalers: McKesson Corp. (NYSE:MCK), Cardinal Health (NYSE:CAH), and Cencora (NYSE:COR). This high level of customer concentration introduces a certain level of risk to AbbVie's business model.

Additionally, the company is expanding its aesthetics portfolio through direct-to-physician sales. In contrast, Novo Nordisk has primarily focused on metabolic health, benefiting from the significant increase in demand for its obesity medications. The company's future growth appears to be tied to maintaining and expanding its lead in this niche market.

When assessing which of these healthcare giants is a better buy in 2026, investors should carefully consider their risk tolerance and investment objectives, as each company presents unique advantages and challenges within the pharmaceutical sector.